Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Our product pipeline candidates utilize the hydrogel technology to provide differentiated drug delivery solutions that are designed to reduce the complexity and burden of current drop or injection regimens by creating sustained release dosage forms that can be tailored to produce the desired drug release profile. It is our intention to develop a product portfolio to overcome the issues of patient compliance and adherence by providing means of more consistent and reliable drug dosing.
Ocular Therapeutix’s lead product candidate, DEXTENZA™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase 3 clinical development targeting mild to moderate glaucoma and ocular hypertension. The Company’s earlier stage assets include OTX-TIC, a sustained release travoprost intracameral implant targeting moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal implants for the treatment of retinal diseases. These injectable implants include OTX-TKI, a tyrosine kinase inhibitor (TKI), and OTX-IVT, in collaboration with Regeneron, an extended release protein-based anti-vascular endothelial growth factor (VEGF) trap. Ocular Therapeutix’s first product, ReSure® Sealant, is approved to seal corneal incisions following cataract surgery.